Core Viewpoint - Hutchison China MediTech (HCM.US) shares rose over 5% to $16.12 following the publication of SACHI III trial results in The Lancet, indicating positive developments in cancer treatment [1] Group 1: Company Developments - Hutchison China MediTech announced the results of the SACHI III trial, which studied the combination therapy of savolitinib and osimertinib for treating EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer patients who progressed after first-line EGFR TKI treatment [1] - Savolitinib is a potent and highly selective oral MET TKI co-developed by AstraZeneca and Hutchison China MediTech, with AstraZeneca responsible for commercialization [1] - Osimertinib is an irreversible third-generation EGFR TKI [1] Group 2: Regulatory Approval - Based on the data from the SACHI study, the combination therapy of savolitinib and osimertinib is expected to receive approval in China by June 2025 [1]
美股异动 | 和黄医药(HCM.US)涨逾5% SACHI III期研究结果于《柳叶刀》发表